Sydney, Sep 11, 2017 AEST (ABN Newswire) - The following investment report by Edison titled 'Preparing for a clinical licence deal in Japan' has been published.

Please contact or connect with Regeneus via social media platforms below if you'd like further information.

To view the Edison Report, please visit:
http://abnnewswire.net/lnk/ZT58EC4E


About Regeneus Ltd

Regeneus Ltd ASX:RGSRegeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell and immuno-oncology technologies to develop a portfolio of innovative cell-based therapies to address significant unmet medical needs in the human and animal health markets with a focus on osteoarthritis and other musculoskeletal disorders, oncology and dermatology.

      


Contact

Sandra McIntosh
Company Secretary and Investor Relations

Tel: +61 2 9499 8010
Fax: +61 2 9499 8020
Mob: +61 450 253 059
Email: investors@regeneus.com.au



Related Companies

Regeneus Ltd      

ABN Newswire This Page Viewed:  (Last 7 Days: 183) (Last 30 Days: 868) 
ANALYTICS: LOGIN HERE

Regeneus Ltd NEWS: RECENT VISITS (7601)

Research Report

Social Media